• 1
    Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991; 43: 923.
  • 2
    IARC. Monographs on the evaluation of carcinogenic risks to humans. Hormonal contraception and post-menopausal hormonal therapy. Vol. 72. Lyon: IARC, 1999.
  • 3
    La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer. An update. Drug Saf 2001; 24: 74154.
  • 4
    La Vecchia C, Negri E, Levi F, Decarli A, Boyle P. Cancer mortality in Europe: effects of age, cohort of birth and period of death. Eur J Cancer 1998; 34: 11841.
  • 5
    Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1990–94, and an overview of trends from 1955 to 1994. Eur J Cancer 1999; 35: 1477516.
  • 6
    La Vecchia C, Franceschi S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev 1999; 8: 297304.
  • 7
    Gnagy S, Ming EE, Devesa SS, Hartge P, Whittemore AS. Declining ovarian cancer rates in US women in relation to parity and oral contraceptive use. Epidemiology 2000; 11: 1025.
  • 8
    Cramer DW, Hutchinson GB, Welch WR, Scully RE, Knapp RC. Factors affecting the association of oral contraceptives and ovarian cancer. N Engl J Med 1982; 307: 104751.
  • 9
    Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, Stolley PD, Rosenshein NB, Schottenfeld D, Engle RL Jr. Epithelial ovarian cancer and combination oral contraceptives. JAMA 1982; 247: 32102.
  • 10
    CASH (Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development). The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316: 6505.
  • 11
    WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 1989; 18: 53845.
  • 12
    Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991; 49: 615.
  • 13
    Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184203.
  • 14
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994; 139: 65461.
  • 15
    Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 318: 96100.
  • 16
    Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R, Morgan M, Wheeler JE, SHARE Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol 2000; 152: 23341.
  • 17
    Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60: 5928.
  • 18
    Tzonou A, Day NE, Trichopoulos D, Walker A, Saliaraki M, Papapostolou M, Polychronopoulou A. The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 1984; 20: 104552.
  • 19
    Polychronopoulou A, Tzonou A, Hsieh C, Kaprinis G, Rebelakos A, Toupadaki N, Trichopoulos D. Reproductive variables, tobacco, ethanol, coffee and somatometry as a risk factors for ovarian cancer. Int J Cancer 1993; 55: 4027.
  • 20
    Parazzini F, La Vecchia C, Negri E, Villa A. Estrogen replacement therapy and ovarian cancer risk. Int J Cancer 1994; 57: 1356.
  • 21
    Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M, La Vecchia C. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001; 12: 33741.
  • 22
    Greggi S, Parazzini F, Paratore MP, Chatenoud L, Legge F, Mancuso S, La Vecchia C. Risk factors for ovarian cancer in central Italy. Gynecol Oncol 2000; 79: 504.
  • 23
    Breslow NE, Day NE. Statistical methods in cancer research. vol. I. The analysis of case-control studies. Lyon: IARC, 1990.
  • 24
    Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE, Study of Health and Reproduction (SHARE) Study Group. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001; 12: 30712.
  • 25
    Narod SA, Risch H, Molslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 4248.
  • 26
    Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, Ben-Baruch G, Fishman A, Menczer J, Ebbers SM, Tucker MA, Wacholder S, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and non-carriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 23540.
  • 27
    Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140: 58597.
  • 28
    Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94: 328.
  • 29
    Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis 1987; 40 (Suppl 2): 59S69S.